❗️🫀 Nueva clasificación #IAM
La nueva clasificación busca que el diagnóstico de IAM refleje mejor qué mecanismo está produciendo la lesión miocárdica, facilitando una aplicación más consistente en la práctica clínica 💪
#ESCGuidelines#ESCCongress
Una gran experiencia el poder presentar lo que se hace en LATAM (Ecuador 🇪🇨) en @escardio y haber compartido con @WomenAs1 un grupo maravilloso. Muy agradecida por todo. Seguimos caminando 🫀!
🫀 #REACT at #ESCCongress#Hotline
How early does atherosclerosis really begin?
16,808 adults, age 18–70 without known ASCVD underwent coronary, carotid & femoral imaging
🔎 Silent atherosclerosis: 57.1% overall
➡️ Already present in ~1 in 13 adults aged 18–29
➡️ ~9 in 10 by age 60–70!
💃🏻Women: steep rise during midlife, around menopausal transition; men developed atherosclerosis ~5–10 years earlier
🫀Atherosclerosis begins decades before clinical events—and often before conventional risk scores identify high risk. REACT should make us think about prevention much earlier
Next question: can imaging-guided early intervention actually prevent progression and events? Or should we just work to prevent CVD in everyone?
📄 @NEJM
https://t.co/rcQrmJz8Er
#ASCVD #Prevention #WomensHeartHealth #CVPrev
#ESCCongress
Presentación del SCORE2 LAC
Un día histórico para nuestra sociedad y para la comunidad cardiológica de América Latina y el Caribe
Felicitaciones a los investigadores y muchas gracias a los que nos acompañaron en Munich
@DrPontecarlosi@escardio
🫀 #STAREE at #ESCCongress
Do statins benefit healthy adults ≥70 years? Yes!
Atorvastatin 40 mg vs placebo, ~6 years.
❤️ Major CV events: 10.9 vs 15.5/1,000 person-years
HR 0.70 (95% CI 0.61–0.82) ✅
🧠 Disability-free survival (death, dementia or persistent disability): 21.6 vs 23.0/1,000 person-years
HR 0.94 (0.84–1.05) ❌
Takeaway: In older adults without established CVD, statin therapy produced a substantial 30% relative reduction in major CV events, but did not significantly prolong disability-free survival.
📄 @NEJM
https://t.co/L7G1zbMGfQ
#Statins #Prevention #CardioTwitter
Using oral antibiotics for patients with infectious endocarditis after the POET trial publication has resulted in sustained drop in length of hospital stay without jeopardizing safety: https://t.co/hW8DlZ0aMj
#JACC#Endocarditis@JeppeKPetersen@AnnaStahltba
We're still not over yesterday! 😍
Thank you once again to @escardio for your commitment to uplifting women in cardiology and to achieving equity in cardiology.
We wish you all a great #ESCCongress - take what you learned yesterday and remember: you belong here.
#LetsRISE26
“Talent is everywhere, but opportunity is not - especially for women,” said ACC President @Drroxmehran, kicking off RISE at #ESCCongress. “Together let’s rise and shift the future of health care and transform women’s health.” #LetsRISE2026
What a day.
Thank you for an incredible day.
This community is unparalleled.
We’ll be sharing more learning and reflections from the day over the coming weeks.
#LetsRISE26#ESCCongress